Copyright
©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Feb 15, 2016; 8(2): 222-230
Published online Feb 15, 2016. doi: 10.4251/wjgo.v8.i2.222
Evaluation of antibody-dependent cell-mediated cytotoxicity activity and cetuximab response in KRAS wild-type metastatic colorectal cancer patients
Cristiana Lo Nigro, Vincenzo Ricci, Daniela Vivenza, Martino Monteverde, Giuliana Strola, Francesco Lucio, Federica Tonissi, Emanuela Miraglio, Cristina Granetto, Mirella Fortunato, Marco Carlo Merlano
Cristiana Lo Nigro, Daniela Vivenza, Martino Monteverde, Federica Tonissi, Laboratory of Cancer Genetics and Translational Oncology, Oncology Department, S. Croce and Carle Teaching Hospital, 12100 Cuneo, Italy
Vincenzo Ricci, Emanuela Miraglio, Cristina Granetto, Marco Carlo Merlano, Medical Oncology, Oncology Department, S. Croce and Carle Teaching Hospital, 12100 Cuneo, Italy
Giuliana Strola, Laboratory Department, S. Croce and Carle Teaching Hospital, 12100 Cuneo, Italy
Francesco Lucio, Radiotherapy Department, S. Croce and Carle Teaching Hospital, 12100 Cuneo, Italy
Mirella Fortunato, Pathology Department, S. Croce and Carle Teaching Hospital, 12100 Cuneo, Italy
Author contributions: Lo Nigro C, Ricci V and Merlano MC designed the study; Ricci V, Miraglio E and Granetto C enrolled the patients and collected clinical data; Vivenza D, Monteverde M and Tonissi F performed ADCC assays and genotyping analyses; Strola G performed all the cytofluorimetric studies; Fortunato M selected patient’s tumoral samples; Vivenza D and Lucio F performed the statistical analysis; Lo Nigro C, Ricci V and Merlano MC critically visioned the results and were equally involved in the writing of the paper with Vivenza D.
Conflict-of-interest statement: The authors declare no conflicts of interest regarding this manuscript.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Cristiana Lo Nigro, PhD, Laboratory of Cancer Genetics and Translational Oncology, Oncology Department, S. Croce and Carle Teaching Hospital, Via Carle 25, 12100 Cuneo, Italy. lonigro.c@ospedale.cuneo.it
Telephone: +39-0171-616338 Fax: +39-0171-616331
Received: July 29, 2015
Peer-review started: July 31, 2015
First decision: September 29, 2015
Revised: November 27, 2015
Accepted: December 9, 2015
Article in press: December 11, 2015
Published online: February 15, 2016